{"id":39017,"date":"2026-07-06T10:49:00","date_gmt":"2026-07-06T14:49:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=39017"},"modified":"2026-05-20T11:13:00","modified_gmt":"2026-05-20T15:13:00","slug":"the-platform-technology-moat-why-the-single-molecule-patent-no-longer-wins-the-ip-war","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/the-platform-technology-moat-why-the-single-molecule-patent-no-longer-wins-the-ip-war\/","title":{"rendered":"The Platform Technology Moat: Why the Single-Molecule Patent No Longer Wins the IP War"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

For most of the 20th century, pharmaceutical intellectual property was a single-act play. You discovered a molecule, filed a composition-of-matter patent, and collected revenue for twenty years before generics arrived. The model was clean. It rewarded chemistry. It was also, in the long run, suicidal.<\/p>\n\n\n\n

The $300 billion patent cliff looming between 2025 and 2030 is the bill coming due for that model. [1]<\/a> Nearly 200 drugs, including roughly 70 blockbusters, will lose exclusivity in that window. Five of the top ten pharmaceutical companies face revenue exposure exceeding 50% of their current base. [2]<\/a> A single molecule, no matter how good, expires. The companies preparing to survive that cliff are not the ones with the deepest compound libraries. They are the ones who learned to patent the factory, not just the product.<\/p>\n\n\n\n

This article is about that shift: the transition from molecule-centric IP to platform-centric IP, what it looks like across mRNA, RNAi, CRISPR, and antibody-drug conjugates (ADCs), how courts and regulators are responding to it, and what it means for anyone trying to build, buy, or challenge a pharmaceutical IP position today.<\/p>\n\n\n\n

\n\n\n\n

What Is a Platform Technology Patent \u2014 And Why Does It Change the Rules?<\/strong><\/h2>\n\n\n\n

A composition-of-matter patent covers a specific chemical or biological entity \u2014 the molecule itself. Once that patent expires, the molecule is fair game. A platform technology patent covers something more durable: the delivery mechanism, the chemical modification enabling that delivery, the manufacturing process, the conjugation chemistry, or the computational system that identifies targets. These claims do not expire when any single product does.<\/p>\n\n\n\n

The structural difference matters commercially. A molecule patent generates revenue from one product. A platform patent generates revenue from every product built on that platform \u2014 including products that do not yet exist at the time of filing. When Alnylam Pharmaceuticals secured broad claims on GalNAc-conjugated RNAi delivery independent of length, sequence, and disease target, it did not just protect one siRNA drug. It positioned itself to collect licensing fees or block competitors across every liver-targeted RNAi therapeutic in any indication. [3]<\/a> That is a categorically different commercial asset.<\/p>\n\n\n\n

Platform patents also create what strategists call a ‘moat’ \u2014 a barrier that compounds over time as more products are built on the platform. Each new approved drug tied to the platform generates additional method-of-use patents, new regulatory exclusivities, and fresh clinical data that competitors must replicate from scratch. The platform itself becomes harder to design around as the body of surrounding IP grows.<\/p>\n\n\n\n

Platform IP vs. Molecule IP: A Structural Comparison<\/strong><\/h3>\n\n\n\n
Dimension<\/strong><\/th>Molecule Patent<\/strong><\/th>Platform Patent<\/strong><\/th><\/tr><\/thead>
Scope<\/td>Single active ingredient<\/td>Delivery system, chemistry, process applicable to multiple products<\/td><\/tr>
Revenue model<\/td>Royalties from one drug<\/td>Licensing revenue across entire pipeline\/industry<\/td><\/tr>
Expiry risk<\/td>Binary cliff at patent expiry<\/td>Layered, staggered, new filings extend protection continuously<\/td><\/tr>
Competitive threat<\/td>Generic\/biosimilar entry on Day 1 after LOE<\/td>Must design around entire platform; often no viable design-around exists<\/td><\/tr>
M&A valuation driver<\/td>NPV of remaining exclusivity period<\/td>Licensing income + royalty streams + blocking value across industry<\/td><\/tr>
Key legal vulnerability<\/td>Paragraph IV challenge, inter partes review (IPR)<\/td>Written description\/enablement challenges; PTAB challenge to genus claims<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
\n\n\n\n

The $300 Billion Problem That Made Platform Patents Necessary<\/strong><\/h2>\n\n\n\n

The size of the incoming patent cliff concentrates minds. Between 2025 and 2030, GlobalData projects that only 4% of global drug sales will carry patent protection, down from 12% in 2022. [4]<\/a> Merck’s Keytruda, which generated over $29 billion in sales in 2024, faces loss of exclusivity tied to core U.S. patents expiring in 2028. Bristol-Myers Squibb has two drugs, Eliquis and Opdivo, together representing about 45% of revenues, both heading for patent expiry before 2030. [5]<\/a><\/p>\n\n\n\n

Traditional single-molecule lifecycle management \u2014 polymorphs, metabolites, enantiomers, extended-release formulations \u2014 has a documented track record but a ceiling. Generic manufacturers and inter partes review (IPR) petitioners have become highly efficient at attacking these secondary claims. As of 2025, the IPR institution rate for pharmaceutical formulation patents runs at approximately 60\u201370%, with invalidation rates for instituted patents at roughly 65%. [6]<\/a> The old secondary patent playbook is increasingly paper-thin.<\/p>\n\n\n\n

What replaced it is not a single strategy but an ecosystem of approaches, all sharing the same underlying logic: make the platform itself the asset, not the molecule it produces.<\/p>\n\n\n\n

\n

“By filing over 150 patent applications covering everything from dosing regimens to manufacturing processes, Merck has created an IP ‘moat’ that extends well beyond the initial 2028\u20132029 expiration of its core composition-of-matter patents. For investors, the IP valuation includes the ‘defensive NPV’ \u2014 the revenue protected by delaying biosimilar entry by even 24\u201336 months through secondary patent litigation.” \u2014 DrugPatentWatch Strategic Analysis, 2026 [7]<\/a><\/p>\n<\/blockquote>\n\n\n\n

Loss of Exclusivity Timeline: The Drugs at Risk 2025\u20132030<\/strong><\/h3>\n\n\n\n